Protagonist Therapeutics, IncPTGX
What Protagonist Therapeutics, Inc does.
Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases. Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies.
Icotyde™ (icotrokinra) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which underpins the inflammatory response in psoriasis and offers potential in other IL-23-mediated diseases. Icotyde is licensed to Janssen Biotech, Inc., a Johnson & Johnson company (“JNJ”), under a license and collaboration agreement initially entered into in 2017. Following Icotyde’s joint discovery by Protagonist and JNJ scientists, pursuant to the license and collaboration agreement, we were primarily responsible for the development of Icotyde through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. In July 2025 and September 2025, respectively, JNJ submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) and an application to the European Medicines Agency (“EMA”) seeking the first approval of Icotyde for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis. JNJ has disclosed that it expects to launch Icotyde in the United States in 2026, subject to regulatory approval.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| Net income | -$66.2M | -$125.6M | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| Free cash flow | -$73.0M | -$109.0M | -$108.9M | -$70.8M | $182.8M | $56.1M |
More on PTGX.
- Protagonist Therapeutics, Inc summary
- Protagonist Therapeutics, Inc financial statements
- Protagonist Therapeutics, Inc key metrics
- Protagonist Therapeutics, Inc health scores and style box
- Protagonist Therapeutics, Inc earnings
- Protagonist Therapeutics, Inc dividends
- Protagonist Therapeutics, Inc valuation
- Protagonist Therapeutics, Inc ownership and insiders
- Protagonist Therapeutics, Inc peers
Figures from Protagonist Therapeutics, Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.